

CLL MEDICAL FORUM

Bring the cure to reality

📅 5.6 Sat. 14:30-17:30

台北喜來登大飯店 · B2 壽廳

| Time | Topic | Speaker / Moderator |
|-------------|--|---|
| 14:00-14:30 | Registration | |
| 14:30~14:40 | Opening | >> Speaker 周文堅 醫師 / 臺大醫院 |
| 14:40~15:20 | Current and Future Landscape of Chronic Lymphocytic Leukemia | >> Speaker Prof. Mathias Rummel Hospital of the Justus-Liebig University >> Moderator 周文堅 醫師 / 臺大醫院 |
| 15:20~16:00 | The Advanced Treatment for Relapsed/Refractory CLL | >> Speaker Prof. John Seymour Peter MacCallum Cancer Centre >> Moderator 周文堅 醫師 / 臺大醫院 |
| 16:00~16:15 | Coffee Break | |
| 16:15~16:35 | Experience in Rituximab-based Treatment for My CLL Patients | >> Speaker 黃彥閔 醫師 / 基隆長庚醫院 >> Moderator 王銘崇 醫師 / 高雄長庚醫院 |
| 16:35~16:55 | Experience in Venetoclax-based Treatment for My CLL Patients | >> Speaker 黃威翰 醫師 / 花蓮慈濟醫院 >> Moderator 譚傳德 醫師 / 和信治癌中心醫院 |
| 16:55~17:20 | Panel Discussion How Can We Optimally Manage Our Patients with CLL from Diagnosis to Treatment? | >> Speaker All Participants >> Moderator 譚傳德 醫師 / 和信治癌中心醫院 |
| 17:20~17:30 | Closing Remarks | 周文堅 醫師 / 臺大醫院 |

教育積分 / 中華民國血液病學會甲類 2.5 學分



立即報名

講師簡介



abbvie

SANDOZ A Novartis Division

Prof. Mathias Rummel

- Mathias Rummel, MD, PhD
- Head, Department for Hematology
- Hospital of the Justus-Liebig University
- Giessen, Germany



Prof. Mathias Rummel current research focuses on novel treatment approaches in hematological malignancies, most notably Follicular Lymphoma, Mantle Cell Lymphoma, Waldenström's Macroglobulinemia and other indolent lymphomas as well as Chronic Lymphocytic Leukemia (CLL), Hairy Cell Leukemia and also in the non-malignant hematological disorder Immune Thrombocytopenia (ITP).

He is the chair of the large cooperative German Study group indolent Lymphomas (StiL) with more than 220 study sites in Germany and Austria and is the principal investigator of several on-going clinical protocols, in particular of Investigator Initiated Trials (IIT).

Professor Rummel is actively involved in a number of professional scientific societies, including the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the European Haematology Association (EHA), and the German Society of Haematology and Oncology (DGHO).

He is the principal investigator of many clinical trials in Leukemias, Lymphomas, Hairy Cell Leukemia, and Immune Thrombocytopenia (ITP), and has published several book chapters and papers in peerreviewed scientific journals.



Prof. John Seymour

- MBBS, FRACP, PhD
- Director, Department of Clinical Haematology
- Peter MacCallum Cancer Centre & Royal Melbourne Hospital
- Melbourne, Australia

Professor John Seymour AM is a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.

He received his MB, BS degrees from the University of Melbourne in 1987, completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and subsequently received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research. Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group.

He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, an Editor-in-Chief of Leukemia & Lymphoma, and currently on the editorial boards of Blood and the British Journal of Haematology.

He has authored 18 book chapters, >500 peer reviewed publications (with >25,000 literature citations), and >700 conference abstracts. Actively involved in a broad range of collaborative research, Professor Seymour has been the principal investigator on >85 clinical trials and chief investigator on competitive grants awarded >AUD\$18 million funding in the last 10 years. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.



回首頁

The primary purpose of the Event is to provide medical education and facilitate scientific exchange. The access to the Event is restricted to the invited healthcare professionals. The invitation to the Event is not conditional upon your implicitly or explicitly recommending, administering or prescribing Sandoz/AbbVie products nor your offering Sandoz/AbbVie or Sandoz/AbbVie products any preferable treatments. By attending the Event, you consent that Sandoz/AbbVie, their affiliates and any authorized 3rd party may, in accordance with the applicable law(s), collect, process and utilize, including internationally transfer, your personal information, including but not limited to your picture(s) in the Event, for any reasonable purposes such as organizing, conducting, auditing of the Event.